Neurotech International Archives | Page 3 of 6 | Cannabiz

Cannabis executive salaries: who earned what in FY24

by Steve Jones October 16, 2024October 15, 2025

While the majority of Australia’s ASX-listed cannabis firms saw revenues climb in FY24, profitability often remained […]

US FDA rejects Neurotech application for orphan drug status

by Steve Jones October 8, 2024February 25, 2025

Neurotech seeks pharma partners for overseas drug development but will go it alone in Australia

by Steve Jones August 12, 2024August 12, 2024

Company news: ECS Botanics; Althea; InhaleRx; Neurotech International

by Martin Lane and Steve Jones July 10, 2024July 11, 2024

medical cannabis for children

Cannabinoid drug developer holds ‘positive’ talks with TGA as hopes rise of fast-tracking ARTG listing

by Steve Jones June 28, 2024June 28, 2024

Neurotech reports strong trial results as firm raises A$10m to fund drug-registration activities

by Steve Jones April 17, 2024April 18, 2024

Neurotech progresses ASD trial, inks deal with contract research organisation

by Martin Lane April 10, 2024July 16, 2024

Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria

by Steve Jones and Martin Lane February 28, 2024July 16, 2024

Neurotech’s ASD trial extended by another year

by Martin Lane February 13, 2024July 16, 2024

Company news: Canntic; Myleaf; Neurotech

by Martin Lane January 31, 2024July 11, 2024